Product
Sotagliflozin
Aliases
SAR439954
Name
INPEFA
INN Name
sotagliflozin
FDA Approved
Yes
10 clinical trials
1 organization
20 indications
1 document
Indication
Congestive Heart FailureIndication
Type 2 Diabetes MellitusIndication
Chronic Kidney DiseaseIndication
Hypertrophic CardiomyopathyIndication
Diabetic NephropathiesIndication
Kidney FailureIndication
ChronicIndication
Diabetes Mellitus Type 1Indication
Cardiovascular DiseasesIndication
Type 1 DiabetesIndication
Kidney DiseaseIndication
Diabetes MellitusIndication
Type 1Indication
albuminuriaIndication
Diabetes Complications RenalIndication
Diabetic Complications CardiovascularIndication
HypoxiaIndication
HypertrophicClinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal FunctionStatus: Terminated, Estimated PCD: 2020-07-08
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart FailureStatus: Terminated, Estimated PCD: 2020-06-05
Clinical trial
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic CardiomyopathyStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Clinical trial
Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney DiseaseStatus: Not yet recruiting, Estimated PCD: 2028-08-01
Clinical trial
Individual and Combined Endothelin Receptor and SGLT1/2 Antagonism in Adults With Type 1 Diabetes Mellitus and Chronic Kidney Disease: a Phase 2, Multicenter, Open-label Randomized Cross-over TrialStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesStatus: Not yet recruiting, Estimated PCD: 2029-02-01
Clinical trial
SOTA-P-CARDIA Trial: A Randomized Trial of Sotagliflozin in HFpEF Patients Without DiabetesStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Prevention of CKD Progression in Type 1 Diabetes With Long Term Use of SGLTi Avoiding Kidney hypOxia(PLUTO)Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 2 Double-blind Randomised Controlled Trial Studying the Effect of Sotagliflozin Versus Placebo in Individuals With Heart Failure and Type 1 Diabetes.Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic Obstructive And Non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)Status: Recruiting, Estimated PCD: 2026-07-01
Document
DailyMed Label: INPEFAOrganization
Lexicon Pharmaceuticals, Inc.